DOCSLIB.ORG

Prolonged Sinus Pauses Revealing a Paroxysmal Extreme Pain Disorder: Is It a Frequent Situation? Case Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Prolonged Sinus Pauses Revealing a Paroxysmal Extreme Pain Disorder: Is It a Frequent Situation? Case Report iMedPub Journals INTERNATIONAL ARCHIVES OF MEDICINE 2015 http://journals.imed.pub SECTION: PEDIATRICS Vol. 8 No. 228 ISSN: 1755-7682 doi: 10.3823/1827 Prolonged Sinus Pauses Revealing a Paroxysmal Extreme Pain Disorder: Is it a Frequent Situation? CASE REPORT Sahar Mouram1, Abstract Hicham Sabor2, Ibtissam Fellat1 Title: Paroxysmal extreme pain disorder (PEPD) is an autosomal do- minant painful neuropathy with many, but not all, cases linked to 1 Cardiology B Department, Faculty gain-of-function mutations in SCN9A which encodes voltage-gated of Medicine and Pharmacy, Rabat, sodium channel Na. 1.7. It is a very rare condition featured by flushing Morocco. of the lower half of the body and excruciating burning pain caused 2 Cardiology Department, Military Hospital, Faculty of Medicine and by any stimulus below the waist or in the perianal region. PEPD may Pharmacy, Rabat, Morocco. be associated with cardiovascular instability, especially prolonged sinus pauses, and thus has anesthetic implications. Pacemaker implantation Contact information: is the alternative therapeutic option, but its indications have not been clarified yet. Sahar Mouram. Cardiology B Department. Background: This condition is well described in neurological litera- Address: Faculty of Medicine and ture, but to our knowledge, this is the first case report of a patient Pharmacy, Rabat, Morocco. with paroxysmal extreme pain disorder with prolonged sinus pauses Tel: 00212(0)661630785. requiring anesthesia for an epicardial pacemaker even with the peri- operative risk of the pathology. This clinical observation can help for [email protected] a better management and understanding of the cardiac risk compli- cations of PEPD especially for an infant whose diagnostic is frequently made at the stage of complication This clinical observation can put the item on the necessity of establishing recommendations for mana- gement of cardiac complications during PEPD. Case report: We extensively searched the literature on cardiac pa- cing in patients with PEPD and we described a new case of a 9 month old infant who was admitted in the emergency department for an episode of malaise apnea and hemifacial cyanosis relevant to PEPD. The neurologic exploration was normal. The diagnostic was confirmed by genetic study. The 24 hours recording demonstrated long pauses of 15 seconds during the crisis justifying the implantation of epicar- dial pacemaker without peri-operatory complications due to the high anesthetic risk of this pathology. © Under License of Creative Commons Attribution 3.0 License This article is available at: www.intarchmed.com and www.medbrary.com 1 INTERNATIONAL ARCHIVES OF MEDICINE 2015 SECTION: PEDIATRICS Vol. 8 No. 228 ISSN: 1755-7682 J doi: 10.3823/1827 Conclusion: Paroxysmal extreme pain disorder is a highly distincti- ve sodium channelopathy with incompletely carbamazepine-sensitive bouts of pain and sympathetic nervous system dysfunction. It is most likely to be misdiagnosed as epilepsy and, particularly in infancy, as Keywords hyperekplexia and reflex anoxic seizures. Clinicians must evocate this Paroxysmal Extreme Pain diagnostic even any clinical suspicion given the severity of cardiac Disorder; Sinus Pauses; complications. Anesthetic Risk; Pacemaker. Introduction tion, her development was appropriate, and her Paroxysmal extreme pain disorder (PEPD) is an au- laboratory studies were normal including a blood tosomal dominant painful neuropathy with many, glucose level of 5.4 mmol/L. The girl's parents re- but not all, cases linked to gain-of-function mu- ported similar, less profound episodes occurring tations in SCN9A which encodes voltage-gated during crying since the age of 2 months. They sodium channel Na. 1.7. The paper should be of noted that, initially, her head would go back, her interest because this clinical observation can put eyes would roll upwards, and she would become the item on the severity of the cardiac risk com- floppy and limp. These episodes occurred only du- plications of this disease especially for an infant ring crying and lasted a few seconds, followed by whose diagnostic is frequently made at the stage a period of sleepiness. Detailed neurological exam of complication. This clinical observation can help was normal. She was admitted to the pediatric for a better understanding of the management of unit for investigation. anesthetic process Because of the potential for car- Between these episodes, she had been well, and diovascular instability she did not have any evidence of intercurrent illness. She had normal attainment of developmental mi- lestones, and there was no significant past medical Observation history. She had been born at term with no neo- A 9-month-old infant was brought to the emer- natal problems after an uneventful pregnancy. She gency department after an episode of malaise was up-to-date with the vaccination schedule, and and hemifacial cyanosis. Her parent reported that she had not received any vaccinations recently. She the crisis was triggered by crying. The infant had was an only child, and her parents were well with vegetative manifestations like hemifacial redness, no family history of seizures or epilepsy. snorkeling and sweats with foam at the lips, mo- Electrocardiogram demonstrated sinus rhythm tor manifestations like rubbing feet with reduced with a normal QT interval. Provoking cries while consciousness. So the infant turned blue around her vital signs were monitored provoked hyper- the lips and began gasping for air. During this tonia, bradycardia, and brief apnea with associa- time, her eyes “rolled back”, and she did not ted desaturation. She stared straight ahead and interact with her parents. There were no clonic made mouthing movements. She was calmed and movements, and she did not respond to physical given high-flow oxygen. A further similar episode stimulation. On arrival, she was alert and looked occurred later while she was sleeping, this time well. There were no focal findings on examina- without provocation. Follow-up included a brain 2 This article is available at: www.intarchmed.com and www.medbrary.com INTERNATIONAL ARCHIVES OF MEDICINE 2015 SECTION: PEDIATRICS Vol. 8 No. 228 ISSN: 1755-7682 doi: 10.3823/1827 MRI and EEG and were normal. Echocardiography know that mutations of sodium channels cause was without anomalies. The 24 hours rhythm re- not only rare genetic ‘model disorders’ such as in- cording demonstrated the presence of long pau- herited erythromelalgia and channelopathy-asso- ses up to 15 seconds (Figure 1 and 2) during the ciated insensitivity to pain but also common painful attacks thus retaining the indication of a definitive neuropathies. stimulation by an epicardial single chamber pace- The discovery of genetic variants that substantia- maker VVI (St Jude medical Microny II SR, set at a lly alter an individual’s perception of pain has led to back up rate of 80 beats per minute).That was im- a step-change in our understanding of molecular planted without difficulty during anesthesia even events underlying the detection and transmission the high anesthetic risk of the pathology. Since the of noxious stimuli by the peripheral nervous system day of PM implantation and activation, the infant [2]. The voltage-gated sodium ion channel Nav 1.7 has had no more event. is expressed selectively in sensory and autonomic The genetic study showed the presence of mu- neurons; inactivating mutations in SCN9A, which tation in the SCN 9A confirming the diagnosis of encodes Nav 1.7, result in congenital insensitivity PEPD. to pain, whereas gain-of-function mutations in this gene produce distinct pain syndromes. Changes in Nav 1.7 function due to mutations Discussion associated with PEPD, but not IEM, are important Inherited mutations in voltage-gated sodium chan- in INaR generation, suggesting that INaR may play a nels (VGSCs; or Nav ) cause many disorders of ex- role in pain associated with PEPD [1]. This knowled- citability, including epilepsy, chronic pain, myoto- ge provides us with a better understanding of the nia, and cardiac arrhythmias. Understanding the mechanism of INaR generation and may lead to functional consequences of the disease-causing the development of specialized treatment for pain mutations is likely to provide invaluable insight into disorders associated with INaR. Genetic analysis of the roles that VGSCs play in normal and abnormal the SCN9A gene has become an important diag- excitability. nostic test in the characterization of pain syndro- Abnormal pain sensitivity associated with inhe- mes. Although well documented, the correlation rited and acquired pain disorders occurs through between SCN9A genotypes and clinical phenotypes increased excitability of peripheral sensory neurons is still unclear. in part due to changes in the properties of volta- Electrophysiological characterization showed that ge-gated sodium channels (Nav s) [1]. Resurgent this mutation did not affect channel activation but sodium currents (INaR) are atypical currents be- instead resulted in incomplete fast inactivation and lieved to be associated with increased excitabili- a small hyperpolarizing shift in steady-state slow in- ty of neurons and may have implications in pain. activation, characteristics more commonly associa- Mutations in Nav 1.7 (peripheral Nav isoform) as- ted with PEPD [3]. Functional analysis of a number sociated with two genetic pain disorders, inheri- of mutations associated with paroxysmal extreme ted erythromelalgia (IEM) and paroxysmal extreme pain disorder
Load more

Recommended publications
  • Experiences of Rare Diseases: an Insight from Patients and Families
    Experiences of Rare Diseases: An Insight from Patients and Families Unit 4D, Leroy House 436 Essex Road London N1 3QP tel: 02077043141 fax: 02073591447 [email protected] www.raredisease.org.uk By Lauren Limb, Stephen Nutt and Alev Sen - December 2010 Web and press design www.raredisease.org.uk WordsAndPeople.com About Rare Disease UK Rare Disease UK (RDUK) is the national alliance for people with rare diseases and all who support them. Our membership is open to all and includes patient organisations, clinicians, researchers, academics, industry and individuals with an interest in rare diseases. RDUK was established by Genetic RDUK is campaigning for a Alliance UK, the national charity strategy for integrated service of over 130 patient organisations delivery for rare diseases. This supporting all those affected by would coordinate: genetic conditions, in conjunction with other key stakeholders | Research in November 2008 following the European Commission’s | Prevention and diagnosis Communication on Rare Diseases: | Treatment and care Europe’s Challenges. | Information Subsequently RDUK successfully | Commissioning and planning campaigned for the adoption of the Council of the European into one cohesive strategy for all Union’s Recommendation on patients affected by rare disease in an action in the field of rare the UK. As well as securing better diseases. The Recommendation outcomes for patients, a strategy was adopted unanimously by each would enable the most effective Member State of the EU (including use of NHS resources. the
    [Show full text]
  • Prevalence and Incidence of Rare Diseases: Bibliographic Data
    Number 1 | January 2019 Prevalence and incidence of rare diseases: Bibliographic data Prevalence, incidence or number of published cases listed by diseases (in alphabetical order) www.orpha.net www.orphadata.org If a range of national data is available, the average is Methodology calculated to estimate the worldwide or European prevalence or incidence. When a range of data sources is available, the most Orphanet carries out a systematic survey of literature in recent data source that meets a certain number of quality order to estimate the prevalence and incidence of rare criteria is favoured (registries, meta-analyses, diseases. This study aims to collect new data regarding population-based studies, large cohorts studies). point prevalence, birth prevalence and incidence, and to update already published data according to new For congenital diseases, the prevalence is estimated, so scientific studies or other available data. that: Prevalence = birth prevalence x (patient life This data is presented in the following reports published expectancy/general population life expectancy). biannually: When only incidence data is documented, the prevalence is estimated when possible, so that : • Prevalence, incidence or number of published cases listed by diseases (in alphabetical order); Prevalence = incidence x disease mean duration. • Diseases listed by decreasing prevalence, incidence When neither prevalence nor incidence data is available, or number of published cases; which is the case for very rare diseases, the number of cases or families documented in the medical literature is Data collection provided. A number of different sources are used : Limitations of the study • Registries (RARECARE, EUROCAT, etc) ; The prevalence and incidence data presented in this report are only estimations and cannot be considered to • National/international health institutes and agencies be absolutely correct.
    [Show full text]
  • Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery
    fphar-07-00121 May 7, 2016 Time: 11:45 # 1 REVIEW published: 10 May 2016 doi: 10.3389/fphar.2016.00121 Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery Paola Imbrici1*, Antonella Liantonio1, Giulia M. Camerino1, Michela De Bellis1, Claudia Camerino2, Antonietta Mele1, Arcangela Giustino3, Sabata Pierno1, Annamaria De Luca1, Domenico Tricarico1, Jean-Francois Desaphy3 and Diana Conte1 1 Department of Pharmacy – Drug Sciences, University of Bari “Aldo Moro”, Bari, Italy, 2 Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari “Aldo Moro”, Bari, Italy, 3 Department of Biomedical Sciences and Human Oncology, University of Bari “Aldo Moro”, Bari, Italy In the human genome more than 400 genes encode ion channels, which are transmembrane proteins mediating ion fluxes across membranes. Being expressed in all cell types, they are involved in almost all physiological processes, including sense perception, neurotransmission, muscle contraction, secretion, immune response, cell proliferation, and differentiation. Due to the widespread tissue distribution of ion channels and their physiological functions, mutations in genes encoding ion channel subunits, or their interacting proteins, are responsible for inherited ion channelopathies. These diseases can range from common to very rare disorders and their severity can be mild, Edited by: disabling, or life-threatening. In spite of this, ion channels are the primary target of only Maria Cristina D’Adamo, University of Perugia, Italy about 5% of the marketed drugs suggesting their potential in drug discovery. The current Reviewed by: review summarizes the therapeutic management of the principal ion channelopathies Mirko Baruscotti, of central and peripheral nervous system, heart, kidney, bone, skeletal muscle and University of Milano, Italy Adrien Moreau, pancreas, resulting from mutations in calcium, sodium, potassium, and chloride ion Institut Neuromyogene – École channels.
    [Show full text]
  • And Late-Onset Inherited Erythromelalgia: Genotype–Phenotype Correlation
    doi:10.1093/brain/awp078 Brain 2009: 132; 1711–1722 | 1711 BRAIN A JOURNAL OF NEUROLOGY Early- and late-onset inherited erythromelalgia: genotype–phenotype correlation Chongyang Han,1,2 Sulayman D. Dib-Hajj,1,2 Zhimiao Lin,3 Yan Li,3 Emmanuella M. Eastman,1,2 Lynda Tyrrell,1,2 Xianwei Cao,4 Yong Yang3,* and Stephen G. Waxman1,2,* Downloaded from 1 Department of Neurology and Center for Neuroscience and Regeneration Research, Yale University School of Medicine, New Haven, CT 06510, USA 2 Rehabilitation Research Center, Veterans Affairs Connecticut Healthcare System, West Haven, CT 06516, USA 3 Department of Dermatology, Peking University First Hospital, Beijing 100034, China 4 Department of Dermatology, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 33006, China http://brain.oxfordjournals.org *These authors contributed equally to this work. Correspondence to: Stephen G. Waxman, MD, PhD, Department of Neurology, LCI 707, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520-8018, USA E-mail: [email protected] Correspondence may also be addressed to: Yong Yang, MD, PhD Department of Dermatology, at Yale University on July 26, 2010 Peking University First Hospital, No 8 Xishiku Street, Xicheng District, Beijing 100034, China E-mail: [email protected] Inherited erythromelalgia (IEM), an autosomal dominant disorder characterized by severe burning pain in response to mild warmth, has been shown to be caused by gain-of-function mutations of sodium channel Nav1.7 which is preferentially expressed within dorsal root ganglion (DRG) and sympathetic ganglion neurons. Almost all physiologically characterized cases of IEM have been associated with onset in early childhood.
    [Show full text]
  • Peripheral Arteriovascular Disease Shownotes
    CrackCast Show Notes – Peripheral Arteriovascular Disease – June 2017 www.canadiem.org/crackcast Chapter 87 – Peripheral Arteriovascular Disease Episode Overview: 1. What is an atheroma and how is it formed? 2. What are the classic symptoms of arterial insufficiency? 3. Provide a differential diagnosis for chronic arterial insufficiency. 4. What is blue toe syndrome? What is its significance? 5. Differentiate between thrombotic and embolic limb ischemia based on clinical features. 6. What is the management of an acutely ischemic limb? 7. List three disorders characterized by abnormal vasomotor response. 8. Describe Raynaud's disease and how it’s treated? 9. What is the most common site for an arterial aneurysm in the leg? 10. List four potential sites for upper extremity aneurysms, and their associated underlying causes. 11. Name three types of visceral aneurysms and their associated conditions. 12. List 6 differential diagnosis of an occluded indwelling catheter and describe the management of a suspected line infection. 13. What are the two types of arteriovenous (AV) fistulae used for dialysis? 14. How do you access an AV fistula? 15. List 5 complications of dialysis fistulas and treatment. 16. List the 3 types of thoracic outlet syndrome. What are the typical symptoms of thoracic outlet syndrome? What is a simple bedside test for this condition? 17. List 4 anatomic abnormalities associated with thoracic outlet syndrome. Wisecracks: 1. Describe Buerger’s sign and the ankle brachial index. 2. List the clinical criteria for Buerger’s Disease (5). 3. What is Leriche's syndrome? 4. List 4 types of infectious aneurysms. 5. Differentiate between arterial insufficiency ulcers and venous stasis ulcers.
    [Show full text]
  • Erythromelalgia Misdiagnosed As Cellulitis
    CONTINUING MEDICAL EDUCATION Erythromelalgia Misdiagnosed as Cellulitis LT Mark Eaton, MC, USNR; LCDR Sean Murphy, MC, USNR GOAL To understand erythromelalgia OBJECTIVES Upon completion of this activity, dermatologists and general practitioners should be able to: 1. Describe the clinical presentation of erythromelalgia in patients. 2. Explain the pathophysiology of erythromelalgia. 3. Discuss the treatment options for erythromelalgia. CME Test on page 32. This article has been peer reviewed and is accredited by the ACCME to provide continuing approved by Michael Fisher, MD, Professor of medical education for physicians. Medicine, Albert Einstein College of Medicine. Albert Einstein College of Medicine designates Review date: December 2004. this educational activity for a maximum of 1 This activity has been planned and implemented category 1 credit toward the AMA Physician’s in accordance with the Essential Areas and Policies Recognition Award. Each physician should of the Accreditation Council for Continuing Medical claim only that credit that he/she actually spent Education through the joint sponsorship of Albert in the activity. Einstein College of Medicine and Quadrant This activity has been planned and produced in HealthCom, Inc. Albert Einstein College of Medicine accordance with ACCME Essentials. Drs. Eaton and Murphy report no conflict of interest. The authors report off-label use of aspirin, gabapentin, heparin, lidocaine patches, misoprostol, serotonin reuptake inhibitors, ticlopidine, topical capsaicin, tricyclic antidepressants, and warfarin for the treatment of erythromelalgia. Dr. Fisher reports no conflict of interest. This case report examines the presentation of a Treatments target symptom alleviation, as well as patient with erythromelalgia that was misdiag- diagnosis and treatment of causative factors.
    [Show full text]
  • Muscle Channelopathies
    Muscle Channelopathies Stanley Iyadurai, MSc PhD MD Assistant Professor of Neurology, Neuromuscular Specialist, OSU, Columbus, OH August 28, 2015 24 F 9 M 18 M 23 F 16 M 8/10 Occasional “Paralytic “Seizures at “Can’t Release Headaches Gait Problems Episodes” Night” Grip” Nausea Few Seconds Few Hours “Parasomnia” “Worse in Winter” Vomiting Debilitating Few Days Full Recovery Full Recovery Video EEG Exercise – Light- Worse Sound- 1-2x/month 1-2x/year Pelvic Red Lobster Thrusting 1-2x/day 3-4/year Dad? Dad? 1-2x/year Dad? Sister Normal Exam Normal Exam Normal Exam Normal Exam Hyporeflexia Normal Exam “Defined Muscles” Photophobia Hyper-reflexia Phonophobia Migraines Episodic Ataxia Hypo Per Paralysis ADNFLE PMC CHANNELOPATHIES DEFINITION Channelopathy: a disease caused by dysfunction of ion channels; either inherited (Mendelian) or acquired/complex (Non-Mendelian, e.g., autoimmune), presenting either in neurologic or non-neurologic fashion CHANNELOPATHY SPECTRUM CHARACTERISTICS Paroxysmal Episodic Intermittent/Fluctuating Bouts/Attacks Between Attacks Patients are Usually Completely Normal Triggers – Hunger, Fatigue, Emotions, Stress, Exercise, Diet, Temperature, or Hormones Muscle Myotonic Disorders Periodic Paralysis MUSCLE CHANNELOPATHIES Malignant Hyperthermia CNS Migraine Episodic Ataxia Generalized Epilepsy with Febrile Seizures Plus Hereditary & Peripheral nerve Acquired Erythromelalgia Congenital Insensitivity to Pain Neuromyotonia NMJ Congenital Myasthenic Syndromes Myasthenia Gravis Lambert-Eaton MS Cardiac Congenital
    [Show full text]
  • Thesis Submitted for the Degree of Doctor of Philosophy University of Bath Department of Pharmacy and Pharmacology April 2013
    University of Bath PHD Evaluating digital vascular perfusion and platelet dysfunction in Raynaud’s phenomenon and systemic sclerosis Pauling, John Award date: 2013 Awarding institution: University of Bath Link to publication Alternative formats If you require this document in an alternative format, please contact: [email protected] General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 07. Oct. 2021 Evaluating digital vascular perfusion and platelet dysfunction in Raynaud’s phenomenon and systemic sclerosis submitted by John D Pauling A thesis submitted for the degree of Doctor of Philosophy University of Bath Department of Pharmacy and Pharmacology April 2013 COPYRIGHT Attention is drawn to the fact that copyright of this thesis rests with the author. A copy of this thesis has been supplied on condition that anyone who consults it is understood to recognise that its copyright rests with the author and that they must not copy it or use material from it except as permitted by law or with the consent of the author.
    [Show full text]
  • ORD Resources Report
    Resources and their URL's 12/1/2013 Resource Name: Resource URL: 1 in 9: The Long Island Breast Cancer Action Coalition http://www.1in9.org 11q Research and Resource Group http://www.11qusa.org 1p36 Deletion Support & Awareness http://www.1p36dsa.org 22q11 Ireland http://www.22q11ireland.org 22qcentral.org http://22qcentral.org 2q23.org http://2q23.org/ 4p- Support Group http://www.4p-supportgroup.org/ 4th Angel Mentoring Program http://www.4thangel.org 5p- Society http://www.fivepminus.org A Foundation Building Strength http://www.buildingstrength.org A National Support group for Arthrogryposis Multiplex http://www.avenuesforamc.com Congenita (AVENUES) A Place to Remember http://www.aplacetoremember.com/ Aarons Ohtahara http://www.ohtahara.org/ About Special Kids http://www.aboutspecialkids.org/ AboutFace International http://aboutface.ca/ AboutFace USA http://www.aboutfaceusa.org Accelerate Brain Cancer Cure http://www.abc2.org Accelerated Cure Project for Multiple Sclerosis http://www.acceleratedcure.org Accord Alliance http://www.accordalliance.org/ Achalasia 101 http://achalasia.us/ Acid Maltase Deficiency Association (AMDA) http://www.amda-pompe.org Acoustic Neuroma Association http://anausa.org/ Addison's Disease Self Help Group http://www.addisons.org.uk/ Adenoid Cystic Carcinoma Organization International http://www.accoi.org/ Adenoid Cystic Carcinoma Research Foundation http://www.accrf.org/ Advocacy for Neuroacanthocytosis Patients http://www.naadvocacy.org Advocacy for Patients with Chronic Illness, Inc. http://www.advocacyforpatients.org
    [Show full text]
  • Autoimmune Neurological Syndromes with Anti- CASPR2 Antibodies : Clinical, Immunological and Genetic Characterization Bastien Joubert
    Autoimmune neurological syndromes with anti- CASPR2 antibodies : clinical, immunological and genetic characterization Bastien Joubert To cite this version: Bastien Joubert. Autoimmune neurological syndromes with anti- CASPR2 antibodies : clinical, im- munological and genetic characterization. Neurons and Cognition [q-bio.NC]. Université de Lyon, 2019. English. NNT : 2019LYSE1283. tel-02497489 HAL Id: tel-02497489 https://tel.archives-ouvertes.fr/tel-02497489 Submitted on 3 Mar 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. N°d’ordre NNT : 2019LYSE1283 THESE de DOCTORAT DE L’UNIVERSITE DE LYON opérée au sein de l’Université Claude Bernard Lyon 1 Ecole Doctorale 476 Neurosciences et Cognition Spécialité de doctorat : Neurosciences Soutenue publiquement le 19 décembre 2019, par Bastien Joubert Autoimmune neurological syndromes with anti- CASPR2 antibodies: Clinical, immunological and genetic characterization Devant le jury composé de : Pr Catherine FAIVRE-SARRAILH, Aix Marseille Université Présidente Pr Louise TYVAERT, Université de Lorraine Rapporteure Pr Josep DALMAU, University of Barcelona Rapporteur Dr Viriginie DESESTRET, Université Claude Bernard Lyon 1 Examinatrice Pr Jérôme HONNORAT, Université Claude Bernard Lyon 1 Directeur de thèse REMERCIEMENTS / ACKNOWLEDGEMENTS Je remercie le Professeur Louise Tyvaert, qui m'honore par sa présence au sein de ce Jury de Thèse et a bien voulu juger ce travail.
    [Show full text]
  • Erythromelalgia Presentation and Outcome in 168 Patients
    STUDY Natural History of Erythromelalgia Presentation and Outcome in 168 Patients Mark D. P. Davis, MB, MRCPI; W. Michael O’Fallon, PhD; Roy S. Rogers III, MD; Thom W. Rooke, MD Objective: To describe the demographics, presenta- male, and 46 (27.4%) were male. At presentation, the pa- tion, and outcome in patients with erythromelalgia—a tients’ mean age was 55.8 years (age range, 5-91 years). rare and poorly understood clinical syndrome defined by Symptoms had been present since childhood in 7 pa- the triad of red, hot, painful extremities. tients (4.2%). Six patients (3.6%) had a first-degree rela- tive with erythromelalgia. Symptoms were intermittent Design: Retrospective medical record review with fol- in 163 patients (97.0%) and constant in 5 (3.0%). Symp- low-up by survey questionnaire. toms predominantly involved feet (148 patients [88.1%]) and hands (43 patients [25.6%]). Kaplan-Meier sur- Setting: Large tertiary care medical center. vival curves revealed a significant decrease in survival com- pared with that expected in persons of similar age and Subjects: Patients with erythromelalgia examined at the of the same sex (P,.001). After a mean follow-up of 8.7 Mayo Clinic, Rochester, Minn, between 1970 and 1994. years (range, 1.3-20 years), 30 patients (31.9%) re- ported worsening of, 25 (26.6%) no change in, 29 (30.9%) Intervention: The medical records of 168 patients were improvement in, and 10 (10.6%) complete resolution of analyzed. Follow-up data, which consisted of answers to the symptoms. On a standard health status question- 2 survey questionnaires or the most recent information naire, scores for all but one of the health domains were in the medical record from patients still alive and death significantly diminished in comparison with those in the certificates or reports of death for those deceased pa- US general population.
    [Show full text]
  • Rare Diseases, When Taken Together, Are Are Together, When Taken Diseases, Rare to According at All
    2013 MEDICINES IN DEVELOPMENT REPORT Rare Diseases A Report on Orphan Drugs in the Pipeline PRESENTED BY AMERICA’s biopharmACEUTICAL RESEARCH COMPANIES More Than 450 Medicines in Development for Rare Diseases Rare diseases, when taken together, are A major area of this research targets Orphan Drugs in Development* not that rare at all. In fact, according to rare cancers, accounting for more than Application the National Institutes of Health (NIH), one-third of all rare disease medicines in Submitted 30 million Americans have one of the development. Other top research areas Phase III nearly 7,000 diseases that are officially include genetic disorders, neurologi- Phase II deemed “rare” because alone they each cal conditions, infectious diseases and Phase I affect fewer than 200,000 people in autoimmune disorders. the United States. Sometimes, only Despite some recent victories, research a few hundred patients are known to 105 into treatments for rare diseases is a have a particular rare disease. daunting quest. This ongoing innovation Simply receiving a diagnosis of a rare and the hundreds of new medicines in disease often becomes a frustrating development now offer hope that physi- 85 quest, since many doctors may have nev- cians will have new treatment options er before heard of or seen the disease. for patients confronting a rare disease. This is, however, a time of great progress and hope. Biopharmaceutical 65 Contents research is entering an exciting new era Innovative Orphan Drugs with a growing understanding of the in the Pipeline ......................................... 2 human genome. Scientific advances have given researchers new tools to Orphan Drug Approvals ...........................4 explore rare diseases, which are often Challenges in Clinical Trials ......................6 more complex than common diseases.
    [Show full text]